T therapy Aucatzyl could usher in profitability by 2028, CEO Christian Itin said, but growth from other disease areas will ...

Even though Arvinas and Pfizer appear to have "written off" the drug, in one analyst's view, Rigel believes it can drive adoption among community-treated patients lacking SERD access.

At the ASCGT meeting, scientists reported that Carvykti-treated cells overexpressed the enzyme Granzyme K, which may be ...

The firm said the epidermolysis bullosa cell therapy brought in $8.7 million in Q1 and that it will develop a prostate cancer cell therapy and deprioritize internal ophthalmology programs.

ETX101 reduced seizures and improved neurodevelopmental outcomes, but its impact was unexpectedly attenuated by using the ...

The firm will use the funding to advance therapies for gastroesophageal, liver, and HER2-positive tumors and conduct preclinical studies of an autoimmune candidate.

Attendees at a fireside chat at the ASGCT annual meeting noted disconnects between the agency's stated goal of speeding gene therapies to market and its actions.

The latest decision makes these treatments routinely available after having been accessible only through a managed access scheme.

Regeneron's Otarmeni was recently FDA approved for patients with OTOF-related hearing loss based on CHORD trial results.

NEW YORK – Rigel Pharmaceuticals said on Tuesday it has licensed the proteolysis targeting chimera (PROTAC) therapy Veppanu (vepdegestrant) from Pfizer and Arvinas in a deal worth up to $445 million ...

NEW YORK – Curocell and ProBio, which provides cell therapy manufacturing support to biotechs, say they're one step closer to treating lymphoma patients in South Korea with the autologous ...

The former commissioner pushed a regulatory pathway for rare disease drugs and launched a voucher program for expedited ...